SINGAPORE, March 19, 2014 /CNW/ - Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I.F), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Korean Intellectual Property Office has granted a Notice of Allowance for its 3D/2D switchable optical imaging system for its glasses-free 3D auto-stereoscopic display system. This Notice of Allowance adds to the other global patents, including U.S. patent number 7,944,465 covering Zecotek's glasses-free 3D auto-stereoscopic display system, as the Company moves to fully commercialize its innovative 3D technology and other photonics technology.
"As our 3D display technology gains prominence within the 3D industry, patent protection in leading technological nations, such as Korea, is key to protecting the underlying value of the technology," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "Korea is home to the world`s major display manufacturers and to receive the notice of allowance in this important jurisdiction significantly strengthens our international patent protection with respect to our glasses-free 3D display technology. The patent grant from Korea is in addition to those patents granted in United States, China, Europe, Eurasia, Russia and Australia. We will continue to vigorously protect all of the Company`s underlying technology through patents and litigation where necessary."
Zecotek's 3D display system has significant competitive advantages compared to competing systems. The 3D/2D switchable optical imaging system further improves the core capabilities of the 3D display technology by introducing a software-selectable full-resolution 2D mode with viewing angles and dynamic range/colour depth on par with conventional 2D displays. The patent covers technology for both 3D and 2D modes, dynamic adjustment of viewing angle, number and width of viewing zones as well as the functionality to dynamically control the positioning of different viewing zones.
Zecotek has overcome the main technical barriers required for flat screen form, high definition display technologies, and the Company is looking to co-develop an OLED/LED (organic light emitting diode) based, flat screen, glasses-free, true 3D HD television with a strategic partner. There continues to be significant interest in the 3D industry for a replacement for display systems which require glasses or provide limited views.
About Zecotek's 3D Display System
Zecotek's 3D Display System is based on the auto-stereoscopic principle, but with substantial innovative and patented improvements and represents a new and unique generation of 3D displays. It has the capability of simultaneously presenting 3D and 2D images on the same screen, and for separate views at different viewing angles. Zecotek's true, auto-stereoscopic 3D2D display system requires no eyewear and has an effective viewing angle of 40 degrees with 90 concurrent perspectives allowing for multiple views at the same time. Another unique feature of the Zecotek system is constant motion parallax within the viewing angle. Motion parallax eliminates the sense of imbalance and dizziness during normal observation which can occur with polarized and shutter glasses used with other commercial systems. Furthermore Zecotek's 3D display features the preservation of the base resolution in every perspective view irrespective of the number of such views. This is not true for any other glasses-free displays where the base resolution is divided by the number of views. Zecotek`s white paper on 3D display technology is available on www.zecotek.com.
About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners such as Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), and National NanoFab Center (South Korea). For more information visit www.zecotek.com, follow @zecotek on Twitter and "like" us in Facebook at www.facebook.com/zecotek.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors - mining, oil & gas, technology & life sciences, diversified industries and clean technology - based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2013.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.
Image with caption: "Zecotek (TSX-V: ZMS) - leading the way in photonics (CNW Group/Zecotek Photonics Inc.)". Image available at: http://photos.newswire.ca/images/download/20140319_C5973_PHOTO_EN_38121.jpg
SOURCE: Zecotek Photonics Inc.
Zecotek Photonics Inc.
Michael Minder
T: (604) 783-8291
[email protected]
Share this article